{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:40:31Z","timestamp":1779313231907,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Health, Labor and Welfare"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.antiviral.2015.04.014","type":"journal-article","created":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T09:20:18Z","timestamp":1430817618000},"page":"84-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance"],"prefix":"10.1016","volume":"119","author":[{"given":"Atsuko","family":"Hachiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Ode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Kito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urara","family":"Shigemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.04.014_b0005","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1128\/JVI.07133-11","article-title":"Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity","volume":"86","author":"Brockman","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.014_b0010","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dkq326","article-title":"Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors","volume":"65","author":"Ceccherini-Silberstein","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.04.014_b0015","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.04.014_b0020","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.chom.2014.09.016","article-title":"HIV-1 integrase variants retarget viral integration and are associated with disease progression in a chronic infection cohort","volume":"16","author":"Demeulemeester","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2015.04.014_b0025","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1128\/AAC.00283-13","article-title":"Evaluation of combinations of 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine with clinically used antiretroviral drugs","volume":"57","author":"Hachiya","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.014_b0030","doi-asserted-by":"crossref","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance","volume":"107","author":"Hare","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2015.04.014_b0035","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.1128\/JVI.75.16.7756-7762.2001","article-title":"Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection","volume":"75","author":"Harper","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.014_b0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.04.014_b0045","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase\u2013DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.014_b0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.014_b0055","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows\u2013Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2015.04.014_b0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.virol.2010.12.008","article-title":"Structural biology of retroviral DNA integration","volume":"411","author":"Li","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.04.014_b0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature09517","article-title":"The mechanism of retroviral integration from X-ray structures of its key intermediates","volume":"468","author":"Maertens","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.04.014_b0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Menendez-Arias","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.04.014_b0075","doi-asserted-by":"crossref","first-page":"e52562","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.04.014_b0080","unstructured":"Ode, H., Matsuoka, K., Matsuda, M., Hachiya, A., Hattori, J., Yokomaku, Y., Iwatani, Y., Sugiura, W., 2014. HIV-1 near full-length genome analysis by next-generation sequencing: evaluation of quasispecies and minority drug resistance. In: International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge, Antiviral Therapy, Berlin, Germany, p. A80."},{"key":"10.1016\/j.antiviral.2015.04.014_b0085","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.04.014_b0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1742-4690-5-74","article-title":"Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors","volume":"5","author":"Rhee","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2015.04.014_b0095","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.01534-07","article-title":"Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137)","volume":"82","author":"Shimura","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.014_b0100","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.01791-12","article-title":"Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S\/GSK1349572)","volume":"57","author":"Vavro","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.014_b0105","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.04.014_b0110","first-page":"642","article-title":"2014 Update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Topics Antivir. Med."},{"key":"10.1016\/j.antiviral.2015.04.014_b0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/1471-2164-13-475","article-title":"De novo assembly of highly diverse viral populations","volume":"13","author":"Yang","year":"2012","journal-title":"BMC Genomics"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T17:58:03Z","timestamp":1537639083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":23,"alternative-id":["S0166354215001060"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.04.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}